FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1842783716> ?p ?o ?g. }

• W1842783716 endingPage "1330" @default.
• W1842783716 startingPage "1325" @default.
• W1842783716 abstract "To assess the activity and toxicity profile of combined taxol (paclitaxel), ifosfamide, and platinum (cisplatin) (TIP) in patients with recurrent or metastatic squamous cell carcinoma (SCC) of the head and neck.Recurrent or metastatic head and neck SCC patients received paclitaxel 175 mg/m2 in a 3-hour infusion on day 1; ifosfamide 1,000 mg/m2 in a 2-hour infusion on days 1 through 3; mesna 600 mg/m2 on days 1 through 3; and cisplatin 60 mg/m2 on day 1, repeated every 3 to 4 weeks. All were premedicated with dexamethasone, diphenhydramine, and cimetidine. Prophylactic hematopoietic growth factors were not permitted.Fifty-two patients were assessable for response and toxicity; 53 for survival (local-regional recurrence alone in 57% and distant metastasis with or without local-regional recurrence in 43%). Overall response rate was 58% (30 of 52) of patients; complete response rate was 17% (nine of 52) of patients, with six complete responses that continued for a median 15.7+ months. Median follow-up of all patients was 17.7 months. Median survival was 8.8 months (95% confidence interval [CI] 8.1 to 17.5 months). Toxicity was relatively well tolerated and caused no deaths. The most frequent moderate-to-severe toxicity (90% of patients) was transient grades 3 to 4 neutropenia; neutropenic fever occurred in 27%. Grade 3 peripheral neuropathy occurred in three patients, none had grade 4. Grade 3 mucositis occurred in only one patient, none had grade 4.TIP had major activity in this setting, with a 58% objective response rate, 17% complete response rate, durable complete responses (six of nine persisting), and relatively well-tolerated toxicity, with no toxic deaths. The activity of TIP, a novel taxol-cisplatin-based regimen, in recurrent or metastatic head and neck SCC should be confirmed in a phase III trial." @default.
• W1842783716 created "2016-06-24" @default.
• W1842783716 creator A5002490436 @default.
• W1842783716 creator A5004459684 @default.
• W1842783716 creator A5008790176 @default.
• W1842783716 creator A5010399375 @default.
• W1842783716 creator A5017034115 @default.
• W1842783716 creator A5021239485 @default.
• W1842783716 creator A5021376796 @default.
• W1842783716 creator A5041570474 @default.
• W1842783716 creator A5059710197 @default.
• W1842783716 creator A5069190968 @default.
• W1842783716 creator A5073466449 @default.
• W1842783716 creator A5085188591 @default.
• W1842783716 creator A5085865726 @default.
• W1842783716 date "1998-04-01" @default.
• W1842783716 modified "2023-10-10" @default.
• W1842783716 title "Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma." @default.
• W1842783716 cites W1978032061 @default.
• W1842783716 cites W1979300931 @default.
• W1842783716 cites W2015167754 @default.
• W1842783716 cites W2037605675 @default.
• W1842783716 cites W2068776651 @default.
• W1842783716 cites W2102551452 @default.
• W1842783716 cites W2167805334 @default.
• W1842783716 cites W2262048850 @default.
• W1842783716 cites W2323590410 @default.
• W1842783716 cites W2399761312 @default.
• W1842783716 cites W2406213538 @default.
• W1842783716 cites W2409844241 @default.
• W1842783716 cites W2413579470 @default.
• W1842783716 cites W53703316 @default.
• W1842783716 doi "https://doi.org/10.1200/jco.1998.16.4.1325" @default.
• W1842783716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9552033" @default.
• W1842783716 hasPublicationYear "1998" @default.
• W1842783716 type Work @default.
• W1842783716 sameAs 1842783716 @default.
• W1842783716 citedByCount "106" @default.
• W1842783716 countsByYear W18427837162012 @default.
• W1842783716 countsByYear W18427837162013 @default.
• W1842783716 countsByYear W18427837162014 @default.
• W1842783716 countsByYear W18427837162015 @default.
• W1842783716 countsByYear W18427837162016 @default.
• W1842783716 countsByYear W18427837162018 @default.
• W1842783716 countsByYear W18427837162020 @default.
• W1842783716 countsByYear W18427837162021 @default.
• W1842783716 countsByYear W18427837162022 @default.
• W1842783716 countsByYear W18427837162023 @default.
• W1842783716 crossrefType "journal-article" @default.
• W1842783716 hasAuthorship W1842783716A5002490436 @default.
• W1842783716 hasAuthorship W1842783716A5004459684 @default.
• W1842783716 hasAuthorship W1842783716A5008790176 @default.
• W1842783716 hasAuthorship W1842783716A5010399375 @default.
• W1842783716 hasAuthorship W1842783716A5017034115 @default.
• W1842783716 hasAuthorship W1842783716A5021239485 @default.
• W1842783716 hasAuthorship W1842783716A5021376796 @default.
• W1842783716 hasAuthorship W1842783716A5041570474 @default.
• W1842783716 hasAuthorship W1842783716A5059710197 @default.
• W1842783716 hasAuthorship W1842783716A5069190968 @default.
• W1842783716 hasAuthorship W1842783716A5073466449 @default.
• W1842783716 hasAuthorship W1842783716A5085188591 @default.
• W1842783716 hasAuthorship W1842783716A5085865726 @default.
• W1842783716 hasConcept C126322002 @default.
• W1842783716 hasConcept C141071460 @default.
• W1842783716 hasConcept C2776694085 @default.
• W1842783716 hasConcept C2777063308 @default.
• W1842783716 hasConcept C2777506904 @default.
• W1842783716 hasConcept C2778239845 @default.
• W1842783716 hasConcept C2778496288 @default.
• W1842783716 hasConcept C2778850193 @default.
• W1842783716 hasConcept C2780376820 @default.
• W1842783716 hasConcept C29730261 @default.
• W1842783716 hasConcept C71924100 @default.
• W1842783716 hasConcept C90924648 @default.
• W1842783716 hasConceptScore W1842783716C126322002 @default.
• W1842783716 hasConceptScore W1842783716C141071460 @default.
• W1842783716 hasConceptScore W1842783716C2776694085 @default.
• W1842783716 hasConceptScore W1842783716C2777063308 @default.
• W1842783716 hasConceptScore W1842783716C2777506904 @default.
• W1842783716 hasConceptScore W1842783716C2778239845 @default.
• W1842783716 hasConceptScore W1842783716C2778496288 @default.
• W1842783716 hasConceptScore W1842783716C2778850193 @default.
• W1842783716 hasConceptScore W1842783716C2780376820 @default.
• W1842783716 hasConceptScore W1842783716C29730261 @default.
• W1842783716 hasConceptScore W1842783716C71924100 @default.
• W1842783716 hasConceptScore W1842783716C90924648 @default.
• W1842783716 hasIssue "4" @default.
• W1842783716 hasLocation W18427837161 @default.
• W1842783716 hasLocation W18427837162 @default.
• W1842783716 hasOpenAccess W1842783716 @default.
• W1842783716 hasPrimaryLocation W18427837161 @default.
• W1842783716 hasRelatedWork W181853034 @default.
• W1842783716 hasRelatedWork W1991291760 @default.
• W1842783716 hasRelatedWork W2006022537 @default.
• W1842783716 hasRelatedWork W2030818757 @default.
• W1842783716 hasRelatedWork W2033332523 @default.
• W1842783716 hasRelatedWork W2043437720 @default.
• W1842783716 hasRelatedWork W2088165357 @default.

• next